{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:04:12Z","timestamp":1776405852245,"version":"3.51.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immunotherapy has revolutionized cancer treatment. However, the duration of treatment and the timing of discontinuation are major concerns. Current pivotal trials predominantly advocate for a fixed two-year regimen of immune checkpoint inhibitors (ICIs), exemplified by pembrolizumab and toripalimab, as first-line therapy for patients with advanced malignancies. Alternatively, for specific ICIs, including nivolumab, camrelizumab, and tislelizumab, continuous administration until disease progression has emerged as a favored approach. Nevertheless, whether to discontinue treatment after two years remains intensely debated within the medical community, underscoring the need for further research to clarify optimal treatment durations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>In November 2018, a 44-year-old male presented with a persistent headache. Following a positive nasopharyngeal mucosal biopsy, he was diagnosed with non-keratinizing undifferentiated carcinoma of the nasopharynx cT4N2M0. An Epstein-Barr Virus (EBV) DNA load of 800 copies\/mL was detected. The patient completed two cycles of induction chemotherapy with liposomal paclitaxel and nedaplatin, followed by platinum-based concurrent chemoradiotherapy, resulting in a progression-free survival (PFS) of 23.6 months. The EBV DNA load dropped significantly to 190 copies\/mL. However, during a routine examination in January 2021, metastases in the lung and mediastinal lymph nodes were detected, and the EBV DNA load was measured at 2200 copies\/mL. Consequently, surgical intervention was performed, followed by radiotherapy and two years of ICI treatment. Throughout the ICI maintenance period, the EBV DNA level remained consistently below the limit of detection. Remarkably, three months after treatment discontinuation, the patient exhibited a rebound in EBV DNA (1620 copies\/mL). Nevertheless, imaging scans revealed no evidence of tumor progression. Following an ICI rechallenge, the patient\u2019s EBV DNA load returned to undetectable levels. The patient continues the ICI therapy and has thus far achieved a PFS of 41.6 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>EBV DNA levels could serve as an informative marker to predict the necessity of therapy discontinuation during immunotherapy maintenance. Notably, a post-discontinuation ICI rechallenge can still yield favorable outcomes potentially accredited to immune memory.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1585844","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:20:58Z","timestamp":1749705658000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term immune checkpoint inhibitor therapy in a patient with metastatic nasopharyngeal carcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Defeng","family":"Qing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2013Positive, advanced non\u2013Small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score >\/= 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000532023","article-title":"Drug-off criteria in patients with hepatocellular carcinoma who achieved clinical complete response after combination immunotherapy combined with locoregional therapy","volume":"12","author":"Kudo","year":"2023","journal-title":"Liver Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v119.5","article-title":"Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1186\/s12885-024-12564-4","article-title":"Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy","volume":"24","author":"Lin","year":"2024","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1560897","article-title":"Combining interleukin 6 and EBV DNA levels predicts survival outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving chemoimmunotherapy","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00131","article-title":"Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: checkMate 153","volume":"38","author":"Waterhouse","year":"2020","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v128.4","article-title":"Long-term outcomes in patients with advanced and\/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)","volume":"128","author":"Kim","year":"2022","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32770","article-title":"Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma","volume":"126","author":"Chen","year":"2020","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e220587","DOI":"10.1001\/jamanetworkopen.2022.0587","article-title":"Association of plasma epstein-barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 immunotherapy","volume":"5","author":"Xu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.314","article-title":"Mechanism-based cancer therapy: resistance to therapy, therapy for resistance","volume":"34","author":"Ramos","year":"2015","journal-title":"Oncogene"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1585844\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:20:59Z","timestamp":1749705659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1585844\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2025.1585844"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1585844","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1585844"}}